SCHEMBL7710786

SCHEMBL7710786

CC1Oc2ccc(CN(Cc3ccc([N+](=O)[O-])cc3)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1D1 P20393 1/20 0.39
MMP1 P03956 3/20 0.36
MMP2 P08253 3/20 0.36
MMP9 P14780 3/20 0.36
MMP8 P22894 3/20 0.36
MMP13 P45452 3/20 0.36
HIF1A Q16665 4/20 0.35
EPAS1 Q99814 4/20 0.35
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
GUSB P08236 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 1/20 0.33
SLC2A1 P11166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6309020 0.97 MMP1 (0.37) NR1D1MMP1MMP2MMP9MMP8
SCHEMBL7710826 0.92 NR3C2 (0.38) GUSBHDAC3HDAC1HDAC2NCOR2
SCHEMBL7704907 0.88 HSD17B10 (0.38) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL7704945 0.88 HDAC3 (0.44) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7704932 0.87 HDAC3 (0.35) NR1D1HDAC3HDAC1HDAC2NCOR2
SCHEMBL6305346 0.87 PARP1 (0.44) NR1D1MMP1MMP2MMP9MMP8
SCHEMBL7711220 0.86 HDAC3 (0.34) HIF1AEPAS1HDAC3HDAC1HDAC2
SCHEMBL7708363 0.86 TP53 (0.35) HDAC3HDAC1HDAC2NCOR2MAPT
SCHEMBL7711422 0.86 HSD17B10 (0.36) NR1D1HDAC3HDAC1HDAC2NCOR2
SCHEMBL6309617 0.86 HDAC1 (0.43) HDAC3HDAC1HDAC2NCOR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed